Human papillomavirus (types 16 and 18) recombinant, as04 adjuvanted vaccine
Brand: Cervarix®
PBAC's latest decision on Human papillomavirus (types 16 and 18) recombinant, as04 adjuvanted vaccine: Recommended (2007). Considered for Prophylactic vaccination of 12 and 13 year old girls (with a two-year catch up program for girls and women aged 13-26) against cervical cancer and precancerous lesions associated with HPV-16 and HPV-18.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
$75k/QALY
Range: $45k/QALY–$75k/QALY
Submissions
2
first 2007
Submissions
2
2007 → 2007
Eligible population
12 and 13 year old girls (with a two-year catch up program for girls and women aged 13-26) against cervical cancer and precancerous lesions associated with HPV-16 and HPV-18
Therapy area
Immunology
Evidence base
RCT
Comparator
Gardasil
Economic model
CUA
Risk sharing
Risk-sharing arrangement in place — The sponsor has indicated that it is willing to develop an appropriate risk sharing arrangement to address any uncertainties surrounding the inclusion of Cervarix on the NIP.
Submission history
Jul 2007: Not recommended
Nov 2007: Recommended · Authority Required — ICER $75k/QALY